eGenesis Receives FDA Clearance for Gene-Edited...
Sep. 10, 2025
Press Release Service
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
- Jan. 5, 2023
January 05, 2023 04:05 PM Eastern Standard Time
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event in the first patient dosed with nula-cel, and the company’s conclusion that the event is likely related to study treatment. As a result, the company will not meet its guidance for initial proof-of-concept data in mid-2023.
Read the PR here
Tags
Latest News
CLINICAL TRIALS
IND Enabling
Phase I
Phase II
Phase III
Type 1 Primary Hyperoxaluria, PH1, (NCT06892301)
Sponsors:
Guangzhou Women and Children's Medical Center
Sponsors:
Guangzhou Women and Children's Medical Center
IND Enabling
Phase I
Phase II
Phase III
End-Stage Renal Disease, (NCT07053462)
Sponsors:
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Sponsors:
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
IND Enabling
Phase I
Phase II
Phase III
